患者在新加坡接受了4次PRRT治疗,但全身多发骨转移和肝转移的病灶依然存在,疼痛加剧,行动也变得困难。 在西南医科大学附属医院,患者接受了225Ac-DOTATATE治疗。仅仅在首次治疗后的3天,患者的疼痛就明显减轻,行动也恢复自如,生活自理。经过5次225Ac-DOTATATE治疗,骨转移和肝转移的病灶明显缩小,患者的病情得到了显著改善。
P129 Introduction: RYZ101 (225Ac-DOTATATE) is a first-in-class, highly potent alpha-emitting radiopharmaceutical therapy being developed for the treatment of somatostatin receptor 2-expressing (SSTR2+) solid tumors. ACTION-1 ([NCT05477576][1]) is a 2-part, global, randomized, controlled, ...
Majority of the patients experienced these AEs at the time of amino acid infusion which was administered during 225Ac-DOTATATE therapy and was resolved after few hours of amino acid infusion. All the other AEs such as fatigue or asthenia, diarrhoea, appetite loss, abdominal pain, abdominal ...
225Ac-DOTATATE therapyTargeted alpha therapyParagangliomaThe evidence from this study suggests 225 Ac-DOTATATE therapy is effective and safe in the treatment of advanced-stage PGLs and also reports a clear benefit even in patient's refractory to the previous 177 Lu-PRRT....
Post-therapy imaging of 225Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumorNEUROENDOCRINE tumorsSINGLE-photon emission computed tomographyCOLLIMATORSPOSITRON emission tomographyEuropean Journal of Nuclear Medicine and Molecular Imaging -...
Conclusion: The preliminary results of this study suggest that [225Ac]Ac-DOTATATE is stable, safe, and effective for treating advanced and [177Lu] Lu-DOTATATE-refractory NETs. However, prospective studies are needed to determine the impact of treatment ...
225Ac-DOTATATE targeted alpha therapyBackground: The curative option for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is surgery, but as the majority of the patients are diagnosed at theBallal, SanjanaYadav, Madhav PrasadBal, Chandrasekhar...
The DCR was 83.3% (5/6) in patients who were previously treated with 177Lu-DOTATATE. According to the EORTC QLQ-C30 v3.0 score, most symptoms improved after 225Ac-DOTATATE treatment, with only diarrhea showing no improvement. Grade III/IV hematological, kidney, and liver toxicities were not...
The model was applied to [225Ac]Ac-DOTATATE. Computer simulations were performed in Python for 2 scenarios: (1) the daughters decay at the site of [225Ac]Ac-DOTATATE decay; and (2) the daughters have unique biokinetics, where each decay of [225Ac]Ac-DOTATATE releases221Fr off the ...
RYZ101 (Ac-225 DOTATATE) is comprised of the alpha-emitting radioisotope actinium-225, chemical chelator DOTA, and octreotate (TATE), a somatostatin analogue. In the cell-based competitive radioligand binding assay, RAYZ-10001-La (lanthanum surrogate for RYZ101) showed high binding affinity (Ki...